OraSure Technologies Announces Rapid HCV Testing Initiatives Across the U.S. in Support of National Hepatitis Testing Day
19 5월 2014 - 7:00PM
OraSure Technologies, Inc. (Nasdaq:OSUR) today announced its
support of numerous rapid hepatitis C (HCV) testing initiatives for
National Hepatitis Testing Day, taking place on May 19, 2014. These
testing initiatives, happening across the country, will help
encourage thousands of people in the U.S. to get tested for
hepatitis C with the OraQuick® HCV rapid test.
National Hepatitis Testing Day is an educational initiative of
the U.S. Centers for Disease Control and Prevention's (CDC)
Division of Viral Hepatitis and the U.S. Department of Health and
Human Services. Today marks the third National Hepatitis Testing
Day, which reminds people at risk, including those individuals born
between 1945 and 1965, to be tested, and encourages health care
providers to educate patients about chronic viral hepatitis and
testing.
Key highlights of OraSure's National Hepatitis Testing Day
initiatives include:
Walgreens Hepatitis C Testing with OraQuick® HCV
Walgreens will use the OraQuick® HCV rapid test in a new
hepatitis C testing program now available at select Walgreens in 10
states. Tests are available daily during pharmacy hours with no
appointment necessary, and administered by Walgreens pharmacists.
To find the nearest Walgreens offering hepatitis C testing
services, consumers can call 1-866-WAG-YESS (1-866-924-9377).
NASDAQ Stock Market Closing Bell
OraSure will preside over the closing of the NASDAQ Stock Market
today, May 19. Guest speakers for the market close will include
Walgreens representatives, New York City public health officials,
NYC Council members, representatives from community-based
organizations and others. A live webcast of the NASDAQ Closing Bell
will be available at:
http://www.nasdaq.com/about/marketsitetowervideo.asx.
National Hepatitis Testing Day Events
There are special hepatitis C testing events, using the
OraQuick® HCV rapid test, taking place across the country in 20
states. These include events in New York City, where
community-based healthcare organizations BOOM!Health and Community
Healthcare Network are offering testing in mobile vans stationed in
Times Square, and also in Washington D.C. on Capitol Hill, where a
coalition of hepatitis advocacy organizations are sponsoring a
hepatitis testing event, hosted by more than a dozen members of
Congress.
"We are pleased to be working with so many organizations
dedicated to addressing the hepatitis C epidemic by engaging in
initiatives to raise awareness and educate those at risk," said
Douglas A. Michels, President and CEO of OraSure
Technologies. "Of the 5 million Americans estimated to be
infected with HCV today, most are unaware of their infection. Our
OraQuick® HCV test enables healthcare providers to deliver rapid
results, allowing early diagnosis and linkage to care, treatment
and prevention services."
According to the CDC, HCV is the most common chronic blood-borne
infection in the United States, with approximately 5 million people
infected. It is estimated that one in 30 Baby Boomers (adults born
between 1945 and 1965) have chronic hepatitis C and up to 75
percent of the people infected with HCV are unaware of their
infection. The CDC, the U.S. Preventative Services Task Force
(USPSTF), and the American Association for the Study of Liver
Diseases (AASLD) have all issued guidance that recommends HCV
testing for at-risk individuals including all Baby Boomers.
OraQuick® HCV is the first and only FDA-approved and CLIA-waived
point of care test for detection of HCV infection in at-risk
individuals. The simple platform enables healthcare providers to
deliver a diagnosis based on lab-accurate test results in 20
minutes, using venipuncture or fingerstick blood.
About OraSure Technologies
OraSure Technologies is a leader in the development, manufacture
and distribution of point of care diagnostic and collection devices
and other technologies designed to detect or diagnose critical
medical conditions. Its innovative products include rapid tests for
the detection of antibodies to HIV and HCV at the point of care and
testing solutions tests for detecting various drugs of abuse. The
Company sells the OraQuick® In-Home HIV Test, the first and only
rapid HIV test approved by the U.S. Food and Drug Administration
for sale to the consumer over-the-counter market in the U.S. In
addition, the Company is a leading provider of oral fluid sample
collection, stabilization and preparation products for molecular
diagnostic applications. OraSure's portfolio of products is sold
globally to various clinical laboratories, hospitals, clinics,
community-based organizations and other public health
organizations, research and academic institutions, distributors,
government agencies, physicians' offices, and commercial and
industrial entities. The Company's products enable healthcare
providers to deliver critical information to patients, empowering
them to make decisions to improve and protect their health.
For more information on OraSure Technologies, please visit
www.orasure.com.
CONTACT: Media Contact:
Jennifer Moritz
Zer0 to 5ive for OraSure Technologies
917-748-4006
jmoritz@0to5.com
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
OraSure Technologies (NASDAQ:OSUR)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024